This article is more than 5 years old. Information may no longer be current.
Patents issued for SciFluor’s topical solution for retinal diseases
The European Patent Office has issued a patent for SF0166, a topical ophthalmic solution for retinal diseases, according to a press release from SciFluor Life Sciences.
SF0166, a potent and selective small molecule inhibitor of integrin alpha V beta 3, is in clinical development for both diabetic macular edema and neovascular age-related macular degeneration, the release said. It is delivered as an eye drop.
The United States Patent and Trademark Office previously issued five patents for intellectual property protection of SF0166, as well as its methods of use, through 2034.
“The patent issued by the European Patent Office, as well as earlier patents issued by U.S. Patent and Trademark Office, support our global intellectual property strategy based on the unique ability of SF0166 to penetrate to the back of the eye, which could improve patient outcomes in retinal diseases as well as potentially reduce the need for intraocular injections,” Scott Edwards, SciFluor vice president and general manager, said in the release.